Intro
It has been suggested that endocrine disrupting chemicals (EDCs) mimic the steroid
hormone and/or inhibit the action of steroid hormones or endocrine system through
classical and nonclassical pathways of steroid hormone as well as
receptor-independent mechanisms ( Keith,
1997 ; Krimsky, 2000 ; Bandiera, 2006 ; USEPA, 2017). Most of the EDCs
are derived from synthetic organic chemicals and the other are from nature such as
plants. The EDCs have continuously increased through the development of organic
chemical synthetic skills and has threated human health and wild life ( Blair et al., 2000 ; Browne et al., 2018 ). It has been revealed that ECDs can
effect developmental malformations, interfere reproduction, increase cancer risks,
and disturb the function of the immune and nervous system (USEPA, 2017).
Recently we reported that chronic low-dose di-(2-ethylhexyl) phthatlate (DEHP) and
nonylphenol (NP) has nonmonotonic estrogenic effects in mouse reproduction ( Cha et al., 2017 , 2018 ). The last few decades, most of the studies on EDCs have
been based on the pharmacological dogma, that EDCs dose are poisonous ( Vandenberg et al., 2012 ) and toxic ( Vandenberg et al., 2012 ; Mersha et al., 2018 ; van der Weijden et al., 2018 ). Nowadays, EDCs are challenged
in the view of physiological responses and reproductive tract disorders concerned
with dose exposure and periods (Huang & Li, 2014; Mersha et al., 2018 ; van
der Weijden et al., 2018 ). For example, low-dose expose studies have been
done in behavior, Sobolewski et al. 2014 ;
Rebuli et al., 2015 ), obesity ( Brulport et al., 2017 ), metabolism ( Casals-Casas & Desvergne, 2011 ), and
others ( Casals-Casas & Desvergne,
2011 ; Zama & Uzumcu,
2013 ).
NP is derived from nonylphenol ethoxylates (NPEs), which are the metabolites of
alkylphenol ethoxylates. NPEs are widely used in detergents, emulsifiers,
pesticides, paints and plastics, and are also found in sewage ( Purdom et al., 1994 ; Soares
et al., 2008 ). Soto et al.
(1991) and Shelby et al. (1996)
showed that a high-dose NP had uterotrophic effects on rodents, and induced
transcription in ER-transfected HeLa cells and MCF7 cells. Administration with 40
mg/kg/day NP for 14 days on guinea pigs exhibits a prevention of decrease in uterine
weight following castration. The estrogenic effects on histological features of
these animals like those occurring in normal cycling animals ( Danzo et al., 2002 ). In ovariectomized rats, NP at a dose of
100 and 200 mg/kg for 3 days increased uterine weights, thickened of luminal
epithelum, endometrium, and myometrium; and induced proliferation in endometrium
( Zhang et al., 2007 ). Additionally, a
low-dos NP also showed estrogenic effect in female mice ( Cha et al., 2017 ; Di et al., 2018).
DEHP, which is also known as an estrogenic EDC is widely used as plasticizers in
manufacturing polyvinyl chloride, and as it is not covalently bound to plastic, it
is readily emitted to the environment ( Lorz et
al., 2007 ; Halden, 2010 ). DEHP
is found in food wraps, medical devices, and cosmetic products. In rodents, DEHP is
metabolized to mono 2-ethyl hexyl phthalate (MEHP) and 2-ethylhexanol in digestive
tracts, and one of its metabolite, MEHP is observed to have more toxic effects
( Grande et al., 2006 ; Somasundaram et al., 2016 ). It has been
verified that DEHP has reproductive toxicity in humans and animals ( Lovekamp-Swan & Davis, 2003 ; Lorz et al., 2007 ). In vivo
exposure to 2 g/kg DEHP on mature Sprague-Dawley rats decreased ovarian estradiol
production, prolonged estrous cycles, and stopped ovulation ( Davis et al., 1994 ). Oral exposure to 1, 10, and 100 mg/kg
body weight (BW)/day of DEHP on Wistar rats for 30 days did not change BW and wet
uterine weight; but increased ovarian hormones and their receptors expression; and
decreased uterine diameter and numbers of uterine glands ( Somasundaram et al., 2016 ). In addition, it has also been
recently revealed that low-dose DEHP has estrogenic effects in female ( Cha et al., 2018 ; Julien et al., 2018 ).
Although the possible estrogenic effects of low-dose NP and DEHP have been suggested,
the uterine responsibility to chronic low-dose NP and DEHP is not clearly evaluated.
The present study performed to comparatively investigate whether chronic low-dose
have estrogen-like activity on mouse uterus between NP and DEHP.
Results
The wet weight was 0.206±0.019 g in control, 0.177± 0.018 g in 50
μg/L NP, 0.208±0.001 g in 500 μg/L NP, 0.289± 0.157
g in 133 μg/L DEHP, and 0.175±0.003 g in 1,330 μg/L DEHP.
The ration of uterus wet weight to BW (0.0078±0.00119) was significantly
high in 133 μg/L DEHP 133 treated mice ( Fig. 1 ). The rations were 0.00548± 0.00047 in control,
0.00478±0.00054 in 50 μg/L NP, 0.00569± 0.00077 in 500
μg/L NP, and 0.00474±0.00030 in 1,330 μg/L ( Fig. 1 ).
There were no statistical significance between control and EDCs treated groups in
uterine diameter. However, the diameter tended to increase in 133 μg/L
DEHP. Compared with the NP treated groups, the diameter in 133 μg/L DEHP
significantly increased ( Fig. 2 ).
Myometrium thickness significantly increased by 50 μg/L NP, 500
μg/L NP, and 133 μg/L DEHP groups ( Fig. 3 ). On the other hand, the thickness of endometrium was
increased only by DEHP treated groups ( Fig.
3 ).
In the height of luminal epithelial cells, the effects of NP and DEHP were also
different by EDCs. The height was significantly shorter in NP treated groups
than the control. However, there was no difference of the epithelial height in
DEHP treated groups compared with the control ( Fig. 4 ). The number of endometrial glands were less in NP treated
groups than the control and DEHP treated groups. In 133 μg/L DEHP treated
group, the number of glands significantly increased ( Fig. 5F ). There were no difference in morphology of the
glands between treatment groups. All of the groups including the control had
normal, daughter, conglomerated, and few cystic glands ( Fig. 5A–E ).
Esr1, Esr2, Prg, Lox, Egr1 and Muc1 are well
known E 2 downstream genes. As expected the expression levels of
Esr1, Pgr, Lox and Muc1 mRNAs increase by
administration E 2 for 3 days as mentioned in materials and methods.
Yet, Esr2 and Egr1 mRNAs did not increased
( Fig. 6 ). Expression levels of
Esr1 and Lox mRNAs were significantly
higher in 500 μg/L NP, but were significantly lower in DEHP treated
groups than the control (vehicle) and E 2 treated group ( Fig. 6A,D ). In the case of
Esr2 , its expression levels were significantly higher in 50
μg/L NP, but were significantly lower in DEHP treated groups than the
vehicle and E 2 treated group ( Fig.
6B ). Pgr mRNA expression significantly decreased in
500 μg/L NP treatment compared with the control. The expressed mRNA
levels were significantly lower in NP and DEHP treated groups than the
E 2 treated group ( Fig. 6C ).
The expression levels of Muc1 mRNA significantly decreased in
NP treated groups, but significantly increased in DEHP treated groups compared
to the vehicle. Muc1 expression was significantly lower in NP treated groups
than the E 2 treated group. However, its expression was significantly
higher in 133 μg/L DEHP treated group than the E 2 treated
group ( Fig. 6E ). In the case of
Egr1 gene, its expression levels were not different between
groups ( Fig. 6F ) as expected.
Discussion
E 2 (40 ng/day in mice) is known to have uterine hypertrophic effects, as
it increases uterine weight, diameter, endometrium thickness and myometrium
thickness, which corresponds to proliferation on endometrial, myometrial and
epithelial cells as well as hypertrophy of uterine epithelial cells ( Papaconstantinou et al., 2000 ). Previously we
reported the estrogenic effects of chronic low-dose NP and DEHP in the reproduction
of mouse ( Cha et al., 2017 ; Cha et al., 2018 ). Interestingly chronic
low-dose NP and DEHP showed the estrogenic uterine response as seen in the
results.
Chronical exposure with low-dose NP, did not induce uterine weight gain nor did it
increase the diameter. The endometrial thickness did not increase, but the
myometrial thickness increased by 50 and 500 μg/L NP treatment. The height of
luminal epithelial cells and the number of luminal epithelial glands were smaller
than the control both in 50 and 500 μg/L NP. This shows that the chronic
low-dose NP did not induce uterine weight gain, but stimulated the epithelial cells.
Previously, it has been suggested that ERα-specific agonist induces uterine
weight increase but ERβ-specific agonist does not ( Frasor et al., 2003 ). ERα is mainly expressed in the
uterine epithelium, and causes proliferation of epithelial cells based on the
inter-regulation with stromal ERs ( Somasundaram et
al., 2016 ). ERβ modulates the effects of ERα and suppresses
the endometrial proliferation and uterotrophic effects ( Weihua et al., 2000 ; Somasundaram et al., 2016 ). Therefore, it may be suggested that this
examined dose of NP in the present research did not stimulate ERα in stroma
cells and others, but stimulate ERβ. In contrast, the previous suggestion of
NP's role (100 or 200 mg/kg BW) in uterus as hyperplasia factor ( Zhang et al., 2007 ) is denied in the case of
chronic low-dose treatment.
In the case of DEHP, 133 μg/L DEHP induced the gain of uterine weight, and
increased the diameter of uterus. Endometrial thickness increased by the both 133
and 1,330 μg/L DEHP. Myometrial thickness increased by 133 μg/L DEHP.
Additionally, the number of glands increased by 133 μg/L DEHP. These results
indicate that DEHP has nonmonotonic effects in uterus. Recently, it has been
reported that DEHP induced leiomyoma cells to have higher viability and lower
apoptosis rate ( Kim, 2018 ). In
vitro treatment with DEHP has suggested increased viability of
endometrial stromal cells, a precondition to endometriosis ( Scsukova et al., 2016 ). 30 days exposure of 200
μg/kg/day DEHP on uterus of adult female CD-1 mice reduced epithelial cell
proliferation and increased the number of uterine glands. Proliferation of
endometrial stromal cells increased at 200 μg/kg/day, 20 mg/kg/day and 200
mg/kg/day DEHP (Richardson et al., 2018). Besides, it is known that DEHP bind to
ERα but not ERβ ( Satoh et al.,
2001 ; Takeuchi et al., 2005 ).
Combining with the results of Frasor and
Colleagues (2003) , low-dose DEHP (133 μg/L) can work with
ERα in uterus.
In all groups, cystic, daughter and conglomerated glands were observed. It has been
reported that 25-day-old prepubertal mice that were injected 0.1 mL oil as vehicle
for 20 consecutive days did not exhibit daughter and conglomerated glands (Elia et
al., 2008). Another study demonstrated that all those types of glands were observed
in ovariectomized mice that were injected with 20 μg/kg BW/week E 2
for 30–90 ( Gunin et al., 2001 ). The
mice used in the current study were not ovariectomized. Hence, this may reflect the
estrogenic action on endometrial glands of the control group as well as the
experimental groups. Collectively, these histological features indicate weak
potential estrogenic effects of chronic small dose exposure to the chemicals on
mouse uterus.
Pgr is expressed through estradiol-induced ERα action
(Somasundaram et al., 2016). The p-nonylphenol extracted from modified polystyrene
induce cell proliferation with up-regulation of Pgr expression in
MCF7 cells ( Soto et al., 1991 ). At dose of
1, 10, and 100 mg/kg BW/day DEHP for 30 days, Pgr mRNA expression
decreased (Somasundaram et al., 2016). However, interestingly, our results were
controversy to the previous study: Chronic exposure of low-dose NP or DEHP did not
induce higher expression of Pgr mRNA. 500 μg/L NP suppressed
the expression of Pgr mRNA. On the other hand, in the case of
Esr1 and Lox genes, chronic 500 μg/L NP
administration significantly induced higher expression of Esr1 and
Lox mRNAs expression, but DEHPs suppressed their expression
than vehicle and E 2 treatment group. It is known that
Esr2 gene expression is downregulated by E 2 .
Interestingly, Esr2 mRNA expression increased by 50 μg/L NP
administration, and down regulated by chronic low-dose DEHPs. Therefore, the
expression of Esr1, Lox, and Esr2 were similar on agonistic regulation by chronic
low-dose NP and antagonist regulation by chronic low-dose DEHP.
Egr1 is rapidly and transiently up-regulated in uterus by
E 2 ( Guo et al., 2014 ). As
expected in this model, Egr1 mRNA levels did not changed. In the
case of Muc1 gene, its expression is suppressed by chronic low-dose
NP administration, but induced by chronic low-dose DEHP administration as in
dose-dependent manner. Therefore, the expression of Muc1 was
similar on agonistic regulation by chronic low-dose DEHP and antagonist regulation
by chronic low-dose NP.
One of the characteristics of estrogen is biphasic physiological process, likes in
gonadotropin secretion feedback ( Herbison,
2008 ). The chronic low-dose NP and DEHP have dosage dependent gene
expression response in uterus that may be the results of affinity to the ERs, though
the effects of EDCs can be appeared by nuclear receptor, nonclassical receptor, and
receptor-independent mechanisms. ERs are expressed in all cell types of uterus;
ERα is mainly expressed in luminal epithelium and stroma; and ERβ is
localized in myometrium and stroma ( Weihua et al.,
2000 ; Cunha et al., 2004 ; Wada-Hiraike et al., 2006 ). In addition,
ERα and ERβ colocalize in the nuclei of stroma and in the epithelial
cells of gland under the control of E 2 and progesterone. Kuiper and his
colleagues (1998) suggested that some phytoestrogen such as genistein, kaempferol.
apigenin, and kaempferol have a bigger affinity to ERβ than ERα.
Binding affinity of NP to the ERα and ERβ is 0.05 and 0.09,
respectively ( Kuiper et al., 1998 ). NP has
bigger affinity than the others (octylphenol, heptyloxyphenol, etc) and affinity
IC 50 is 2.40–4.73×10 –6 . The
IC 50 of E 2 is 8.99×10 –10 ( Blair et al., 2000 ). On the other hand, DEHP
has very weak competition for the ER and 78% [ 3 H]-E 2 bind to
ER with IC50 is >1.00×10 –3 . Furthermore, ERα
and ERβ have opposite effects on gene transcription ( Paech et al., 1997 ). To uncover the possible physiological
role of chronic-low dose NP and DEHP, further studies in the level of genetic
information usage is needed. This study clearly suggests that chronic lower-dose
administration of NP and DEHP are still potential to have estrogen like roles in
uterus as EDCs. It also shows that chronic low-dose NP has nonmonotonic effects in
uterus.
Materials|Methods
All experimental animals were conducted in accordance with the Guide for the Care
and Use of Laboratory Animals published by the National Institute of Health.
CD-1 mice were maintained under standard condition at Sungshin University.
Circadian rhythm kept under the 14L:10D schedule with light-on at 06:00 and
clean room system. Animals were fed food and drink mentioned in Cha et al. (2017) . Briefly, estrogen-free
rodent diet (2018 Teklad global 18% protein rodent diets; ENVIGO, Madison, WI,
USA) and water were provided ad libitum in glass bottles with
stainless steel sipper tubes from weaning 21 days after birth.
Administration of NP and DEHP followed OECD Guidelines for the Testing of
Chemicals–Test No. 443. 10–12-week-old animals were given NP at a
dose of 50 or 500 μg/L or DEHP at a dose of 133 or 1,330 μg/L
dissolved in drinking water for 10 weeks, considering that a mouse drinks
approximately 4–7 mL/day water. Control group was given water without
test substances. Estrous cycle was checked by smearing daily for first 2 weeks,
then each normal cycling CD-1 female was chosen and bred with a male for 2 weeks
(n=10 / each group). Copulatory plug was checked daily, and after 6 weeks
euthanized by cervical dislocation.
To get ovariectomized mice, 2–3-month-old female mice were anesthetized
with pentobarbital sodium (78 mg/kg BW) and removed ovaries. After a week,
injected subcutaneously (sc.) with 0.1 mL vehicle (control) or 2 μg/kg
E 2 (Cat #: E8875, Sigma) in cottonseed oil for 3 days at 09:00
and sacrificed on the next day.
Uteri were dissected and the uterine wet weights were measured with analytical
electron balancer. A part of uterus was stored at −80° until use
for molecular experiments and the others were fixed overnight in Bouin's
fixative. Fixed uteri were dehydrated with ethyl alcohol using Leica TP 1020,
and embedded in paraffin. The paraffin block was cross-sectioned at 4 μm
(Leica RM2245 microtome) and stained with hematoxylin and eosin Y. Tissues are
microphotographed using Olympus B×60 microscope and Olympus DP71
microscope digital camera. Uterine diameter was measured perpendicularly to
mesometrium-antimesometrium axis on 40× microphotograph with ImageJ
program. Myometrium and endometrium thickness were respectively measured from
longitudinal to circular smooth muscle layers and from luminal surface to
beginning of circular smooth muscle layer on 100× microphotograph with
ImageJ software. Epithelial cell height was measured on 400×
magnification microscope with Tcapture software. Furthermore, number of
endometrial glands was counted and its morphology was analyzed. To get
confidence of the data, at least 4 sections per mouse were analyzed and in all
directions.
Total RNA was extracted using TRI reagent (Cat #: TR 118, Molecular Research
Center, Cincinnati, OH, USA) according to manufacturer's instruction with
modification. Briefly, the sample was homogenized with TRI reagent (1 mL/100 mg)
and kept for 10 min at room temperature (RT). The chloroform (200 μL/mL)
was added and shaken vigorously for 15 sec. Then the mixture was stored for 15
min at RT and centrifuged at 12,000 g for 15 min at 4°. The RNA was
precipitated by mixing isopropanol (0.5 mL/mL), inverting several times,
maintaining at RT for 10 min, and centrifuging at 12,000 g for 8 min at
4°. Purity and concentration of total RNA were assessed by NanoDrop 2000
Spectrophotometer (Cat #: ND-2000, Thermo Scientific, Wilmington, DE, USA). The
total RNA was stored at −80° until used.
First strand cDNA was synthesized using AccuScript High Fidelity Reverse
Transcriptase (Cat #: 600089, Agilent Technologies, CA, USA) according to the
manufacturer's instruction. Shortly, reaction reagents were total RNA,
AccuScript 10× RT buffer 5.0 μL, 0.5 μg/μL oligo dT
primer 1.0 μL, 0.1 μg/μL random primers 1.0 μL,
100mM dNTP mix 2μL, and RNase-free DEPC-treated water. Reaction mixture
was incubated at 65° for 5 min, and cooled slowly at RT to allow the
primers to anneal to RNA for 10 min. Next, 100 mM DTT 4.0 μL, 40
U/μL RNase block ribonuclease inhibitor 2.0 μL (Cat #: 300152-51,
Agilent Technologies, CA, USA), and AccuScript High Fidelity RT 1.0 μL
were added. The mixture was incubated for at 42° for 1 hr and at
70° for 10 min to terminate cDNA synthesis. cDNA was stored at
−20°.
Real-time PCR was performed using SYBR® Premix Ex Taq TM (Cat #:
RR420A, TaKaRa, Japan) and Thermal Cycler Dice Real Time System TP800 (TaKaRa,
Japan). Each reaction was run in triplicate. Dissociation curves were run on all
reactions to ensure amplification of a single product with the appropriate
melting temperature. The fold change in gene expression was calculated using the
ΔΔ Ct method with housekeeping gene, 36B4, as an
internal control.
Results are presented as mean±SEM. Two-way ANOVA was used to evaluate
statistical difference, followed by t -test was performed for
comparisons of two means. Statistical significance was considered at
p <0.05.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.